drugset / Trial / NCT00948155

Measuring Smoking Behaviors While Using Varenicline

NCT00948155

Phase 4 Completed 48 enrolled University of Pennsylvania Pfizer · collab
RandomizedCrossoverDouble-blindTreatment

Summary

This study will demonstrate the behavioral responses to varenicline, helping to better understand its mechanisms. Hypotheses for the study are to observe decreases in smoking topography and nicotine cigarette choice on varenicline, relative to placebo; and decreases on day 21 relative to day 7 during varenicline treatment. We also propose to examine if extended duration of treatment has clinical significance in decreasing smoking behaviors, thus increasing the efficacy of varenicline.

Timeline

Start
2009-01
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg Oral

Indications